Vivoryon Therapeutics N.V.
Developing first-in-class small molecule therapies for age-related and kidney diseases.
VVY | AS
Overview
Corporate Details
- ISIN(s):
- NL00150002Q7
- LEI:
- 3912004AMB0KGZXZYJ15
- Country:
- Germany
- Address:
- Weinbergweg 22, 06120 Halle (Saale)
- Website:
- https://www.vivoryon.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class, small molecule-based therapies for age-related diseases. The company leverages its in-depth expertise in post-translational modifications to develop medicines that modulate the activity and stability of proteins altered in disease. Its most advanced candidate, varoglutamstat, is an orally administered inhibitor of glutaminyl cyclases (QPCT and QPCTL), enzymes implicated in causing or promoting inflammatory, fibrotic, and neurodegenerative diseases, with a primary focus on kidney diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-04 07:28 |
Interim / Quarterly Report
Vivoryon Therapeutics N.V., Halfjaarlijkse financiële verslaggeving
|
English | 1.3 MB | ||
| 2025-08-21 14:00 |
Regulatory Filings
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT)…
|
English | 7.6 KB | ||
| 2025-06-27 07:36 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
|
English | 649.6 KB | ||
| 2025-06-17 07:52 |
Earnings Release
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
|
English | 716.2 KB | ||
| 2025-06-11 07:44 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational …
|
English | 650.9 KB | ||
| 2025-06-06 10:30 |
Regulatory Filings
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND …
|
English | 654.5 KB | ||
| 2025-06-05 14:00 |
Regulatory Filings
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Dis…
|
English | 8.8 KB | ||
| 2025-05-27 07:44 |
Regulatory Filings
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S…
|
English | 686.4 KB | ||
| 2025-04-29 07:02 |
Annual Report
Vivoryon Therapeutics N.V., Jaarlijkse financiële verslaggeving
|
English | 10.7 MB | ||
| 2025-04-25 07:42 |
Capital/Financing Update
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
|
English | 656.2 KB | ||
| 2025-02-11 18:12 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on Febr…
|
English | 629.7 KB | ||
| 2024-12-10 07:49 |
Earnings Release
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on V…
|
English | 674.7 KB | ||
| 2024-11-20 17:07 |
Earnings Release
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
|
English | 2.0 MB | ||
| 2024-10-28 07:39 |
Earnings Release
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutam…
|
English | 722.2 KB | ||
| 2024-10-11 16:18 |
Regulatory Filings
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the Ame…
|
English | 222.8 KB |
Automate Your Workflow. Get a real-time feed of all Vivoryon Therapeutics N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Vivoryon Therapeutics N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Vivoryon Therapeutics N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-04-01 | E. Platzer | Executive member | Buy | 123,809 | 1,299,994.50 EUR |
| 2022-04-01 | U. Dauer | Executive member | Buy | 4,761 | 49,990.50 EUR |
| 2020-12-02 | D.J. von der Osten | Executive member | Buy | 20,000 | 112,400.00 EUR |
| 2020-11-30 | M. Schaeffer | Executive member | Other | 3,867 | N/A |
Peer Companies
